







an Open Access Journal by MDPI

Contemporary Treatment of Colorectal Cancer

Guest Editor:

Dr. Michel Adamina

Chief of Colorectal Surgery, Department of Surgery, Cantonal Hospital Winterthur, Brauerstrasse 15, Postfach 834, 8401 Winterthur, Switzerland

Deadline for manuscript submissions:

10 December 2024

Message from the Guest Editor

Dear Colleagues,

Colorectal cancer is on the rise, with younger patients affected and a higher number of patients overall. Multimodal treatment has led to significant improvements in survival and quality of life with a majority of patients now amenable to a cure, including selected patients with peritoneal or solid organ metastases. Better screening, diagnostic accuracy and refined prognosis, as well as advanced therapeutic concepts, including multimodal neoadjuvant treatment, tailored surgery and multiple lines of adjuvant therapy, all contributed to the significant progress observed in clinical care and outcomes. The present Special Issue addresses the complexity of colorectal cancer and its contemporary management, with several topics highlighted: diagnostic and prognostic markers, cutting-edge imaging, total neoadjuvant and adjuvant therapy, state-of-the-art surgical approaches, including laparoscopic, robotic and transanal surgery, cytoreductive surgery and intraperitoneal chemotherapy, adjuvant chemo- and immunotherapy and best palliative care.

Dr. Michel Adamina *Guest Editor*













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us